Healius (PHCR.F) 주식 개요Healius Limited는 호주의 소비자 및 의료진에게 전문 진단 서비스를 제공합니다. 자세히 보기PHCR.F 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장3/6과거 실적0/6재무 건전성4/6배당0/6강점공정 가치 추정치보다 낮은 87.9% 에서 거래수익은 매년 4.12% 증가할 것으로 예상됩니다.위험 분석주식은 유동성이 매우 낮습니다모든 위험 점검 보기PHCR.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.8440.4% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-998m2b2016201920222025202620282031Revenue AU$1.6bEarnings AU$119.2mAdvancedSet Fair ValueView all narrativesHealius Limited 경쟁사AirSculpt TechnologiesSymbol: NasdaqGM:AIRSMarket cap: US$380.9mNRC HealthSymbol: NasdaqGS:NRCMarket cap: US$431.1mSBC Medical Group HoldingsSymbol: NasdaqGM:SBCMarket cap: US$318.8mFulgent GeneticsSymbol: NasdaqGM:FLGTMarket cap: US$508.4m가격 이력 및 성과Healius 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가AU$0.8452주 최고가AU$0.9752주 최저가AU$0.84베타0.401개월 변동0%3개월 변동n/a1년 변동n/a3년 변동n/a5년 변동n/aIPO 이후 변동-71.53%최근 뉴스 및 업데이트공시 • May 26Private Equity Reportedly Lines Up for Healius's Agilex SaleThe sale of Healius Limited's (ASX:HLS) Agilex Biolabs (Agilex Biolabs Pty. Ltd.) business is attracting a healthy queue of private equity interest. At least two firms are understood to be among those examining the bioanalytical laboratories group being sold via UBS. Local firm Genesis Capital is among the names being mentioned in the context of the process, though it is not clear whether the firm is formally involved. Crescent Capital, which has been active in the healthcare space, is understood not to be among the suitors this time around. Healius is understood to be confident of achieving at least $150 million to $200 million for the business - a sharp markdown on the $301 million it paid in 2021, when the acquisition was struck at 20 times forecast earnings before interest, tax, depreciation and amortisation and pathology assets were commanding top dollar amid the pandemic. Agilex subsequently underperformed against those expectations. Despite the sobering context, the interest is genuine. Bidders are said to believe there is meaningful performance upside in the business. Some of the parties circling Agilex are also understood to have looked at Nucleus Network, the early-phase clinical trials business, suggesting an appetite for scale in the segment. For Healius, a clean exit from Agilex would go some way toward shoring up a balance sheet under pressure following a significant profit downgrade last month that sent shares tumbling more than 19 per cent. With Healius carrying a market value of just $254 million, a buyer acquiring the whole company would effectively be getting the core pathology business for next to nothing - a dynamic that is unlikely to be lost on those now poring over the Agilex information memorandum.공시 • Feb 04Healius Limited to Report Fiscal Year 2026 Results on Aug 09, 2026Healius Limited announced that they will report fiscal year 2026 results on Aug 09, 2026공시 • Jan 27Healius Limited to Report First Half, 2026 Results on Feb 18, 2026Healius Limited announced that they will report first half, 2026 results on Feb 18, 2026공시 • Aug 21Healius Limited Provides Earnings Guidance for the Full Year 2026 and 2027Healius Limited provided earnings guidance for the full year 2026 and 2027. For the 2026, the company expects revenue growth to be consistent with growth in second half of 2025, while maintaining a broadly flat labour cost base. For the 2027, the company continues to expect to achieve high single digit EBIT margins by June 2027.공시 • Aug 19Healius Limited, Annual General Meeting, Oct 30, 2025Healius Limited, Annual General Meeting, Oct 30, 2025.공시 • May 09Healius Limited to Report Fiscal Year 2025 Results on Aug 21, 2025Healius Limited announced that they will report fiscal year 2025 results on Aug 21, 2025더 많은 업데이트 보기Recent updates공시 • May 26Private Equity Reportedly Lines Up for Healius's Agilex SaleThe sale of Healius Limited's (ASX:HLS) Agilex Biolabs (Agilex Biolabs Pty. Ltd.) business is attracting a healthy queue of private equity interest. At least two firms are understood to be among those examining the bioanalytical laboratories group being sold via UBS. Local firm Genesis Capital is among the names being mentioned in the context of the process, though it is not clear whether the firm is formally involved. Crescent Capital, which has been active in the healthcare space, is understood not to be among the suitors this time around. Healius is understood to be confident of achieving at least $150 million to $200 million for the business - a sharp markdown on the $301 million it paid in 2021, when the acquisition was struck at 20 times forecast earnings before interest, tax, depreciation and amortisation and pathology assets were commanding top dollar amid the pandemic. Agilex subsequently underperformed against those expectations. Despite the sobering context, the interest is genuine. Bidders are said to believe there is meaningful performance upside in the business. Some of the parties circling Agilex are also understood to have looked at Nucleus Network, the early-phase clinical trials business, suggesting an appetite for scale in the segment. For Healius, a clean exit from Agilex would go some way toward shoring up a balance sheet under pressure following a significant profit downgrade last month that sent shares tumbling more than 19 per cent. With Healius carrying a market value of just $254 million, a buyer acquiring the whole company would effectively be getting the core pathology business for next to nothing - a dynamic that is unlikely to be lost on those now poring over the Agilex information memorandum.공시 • Feb 04Healius Limited to Report Fiscal Year 2026 Results on Aug 09, 2026Healius Limited announced that they will report fiscal year 2026 results on Aug 09, 2026공시 • Jan 27Healius Limited to Report First Half, 2026 Results on Feb 18, 2026Healius Limited announced that they will report first half, 2026 results on Feb 18, 2026공시 • Aug 21Healius Limited Provides Earnings Guidance for the Full Year 2026 and 2027Healius Limited provided earnings guidance for the full year 2026 and 2027. For the 2026, the company expects revenue growth to be consistent with growth in second half of 2025, while maintaining a broadly flat labour cost base. For the 2027, the company continues to expect to achieve high single digit EBIT margins by June 2027.공시 • Aug 19Healius Limited, Annual General Meeting, Oct 30, 2025Healius Limited, Annual General Meeting, Oct 30, 2025.공시 • May 09Healius Limited to Report Fiscal Year 2025 Results on Aug 21, 2025Healius Limited announced that they will report fiscal year 2025 results on Aug 21, 2025공시 • May 05Healius Limited Announces Fully Franked Special Dividend, Payable on 23 May 2025The Board of Directors of Healius Limited announced that it has resolved to determine to pay a fully franked Special Dividend of approximately $300 million or 41.3 cents per ordinary share. The Special Dividend of 41.3 cents per share will be fully franked. That franking credit equates to 17.7 cents per share or approximately $128 million. Ex-Dividend date is 9 May 2025, Dividend Record Date is 12 May 2025 and Payment date is 23 May 2025.공시 • May 01Affinity Equity Partners (Australia) Pty Limited completed the acquisition of Lumus Imaging from Healius Limited (ASX:HLS).Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million on a cash, debt and equipment-lease free basis on September 23, 2024. Lumus Imaging reported pre AASB 16 EBITDA of AUD 51.3 million and pre AASB 16 EBIT of AUD 34.4 million for period ending June 30, 2024. The sale is subject to customary conditions, including approval by the Foreign Investment Review Board. The transaction is expected to close in 1Q CY2025. The proceeds from the sale will be used to reduce debt, support strategic execution in Pathology and return cash to shareholders. UBS Securities Australia Ltd acted as financial advisor and Bradley Russell, Natalie Bryce and Nicole Pedler of Healius Limited acted as legal advisor for Bradley Russell. As of April 17, 2025 Healius Limited (Healius) today announces that the sale of Lumus Imaging to funds managed by Affinity Equity Partners is now unconditional and the scheduled completion date is 1 May 2025 along with this all conditions precedent including Foreign Investment Review Board approval, have been met. Affinity Equity Partners (Australia) Pty Limited completed the acquisition of Lumus Imaging from Healius Limited (ASX:HLS) on May 1, 2025.공시 • Feb 20Healius Limited Announces Board and Executive ChangesThe Directors of Healius Limited have appointed Mr. Neil Vinson as a Non-Executive Director of Healius to take effect on 1 March 2025. The Board notes that as Mr. Vinson is a current employee of Tanarra Capital, a substantial shareholder, he will not be an Independent director. Mr. Vinson holds a Master of Management (Finance) and a Bachelor of Chemical and Biomolecular Engineering from the University of Melbourne. He joined Tanarra Capital in early 2018 as an Investment Manager, overseeing public market, private equity, and venture capital investments. In this role, he has gained significant board-level and investment experience across healthcare, financial services, retail, and industrial sectors. Previously, Mr. Vinson worked at J.P. Morgan in the Corporate Derivatives and Strategic Solutions team, within the private-side markets business. Audit Committee Chair: Ms Kathy Ostin has been appointed as Chair of the Audit Committee, effective from 1 March 2025. Ms Ostin has been a Non-executive Director of Healius since December 2024 and replaces Charlie Taylor, who has served as the Audit Committee Chair since March 2024. Mr. Taylor remains a Non-executive Director of Healius and Member of the Audit and People & Governance Committees. Resignation of Company Secretary: Mary Weaver has resigned as a Company Secretary with effect from 28 February 2025. Stephen Humphries continues as a Company Secretary and Gillian Nairn will be the person responsible for communications with ASX in relation to Listing Rule matters.공시 • Jan 15Healius Limited to Report First Half, 2025 Results on Feb 20, 2025Healius Limited announced that they will report first half, 2025 results on Feb 20, 2025공시 • Nov 29Healius Limited Announces Board Changes, Effective 1 December 2024The Directors of Healius Limited have appointed Ms Kathy Ostin as an independent Non-Executive Director of the company and accepted the resignation of Mr. Gordon Davis, both to take effect on 1 December 2024. Kathy is an experienced non-executive director and audit and risk committee chair. She brings invaluable experience as a former partner of KPMG and will add to the range of the Board's skills in the areas of finance and accounting, audit, risk, governance and strategy. Gordon also served as Chair of both the Risk and Audit Committees during his tenure.공시 • Sep 24Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million on September 23, 2024. The transaction is expected to close in 1Q CY2025. UBS Securities Australia Ltd acted as financial advisor and Herbert Smith Freehills acted as legal advisor for Healius Limited. Lumus Imaging reported pre AASB 16 EBITDA of AUD 51.3 million and pre AASB 16 EBIT of AUD 34.4 million for period ending June 30, 2024.공시 • Sep 19Healius Limited, Annual General Meeting, Nov 15, 2024Healius Limited, Annual General Meeting, Nov 15, 2024.공시 • Aug 19TPG Capital, PEP Reportedly Still Competing for Healius Lumus ImagingThe Healius Limited (ASX:HLS) Lumus Imaging sale process is shaping up as a two party battle, with TPG Capital, L.P. and Pacific Equity Partners believed to be the last contenders in the contest. "Final" bids for the unit were received on 15 August 2024, but the understanding is that additional due diligence will conducted and then binding bids will be received. IFM, which was considered the frontrunner in the competition, is out, largely because a turnaround approach is required. Such situations typically have less appeal to infrastructure investors like IFM, looking for a steady earnings stream. They're more suited to a private equity firm or a strategic group. Affinity Equity Partners has also left the contest. TPG Capital's bid is being spearheaded by the Australian country head for the US-based private equity firm, Vincent Wong, who is based in Melbourne. PEP, as earlier reported by DataRoom, is working with Stanton Road Partners and Bank of America. Its interest at the start of the auction was considered lukewarm at best, so it will be interesting to see how it progresses through the final stages. No doubt it would snap up Healius at the right price, but it's understood that the Australian listed healthcare provider is seeking about $700 million net, or after transaction and tax costs, with the gross asking price well over that amount. While the potential upside for any buyer could be substantial, it may be tough going in the early stage, with some saying a business clean up is needed. Lumus Imaging, advised by UBS, is the nation's third-largest diagnostic imaging operation behind Sonic and Permira's I-MED. Its earnings before interest, tax, depreciation and amortisation over the next year are forecast to be $60 million - $70 million. Diagnostic imaging is attractive to private equity, with artificial intelligence expected to create upside. Healius is selling its Lumus Imaging unit to drive down its debt and fund its pathology arm, despite the imaging operation being the stronger performer.공시 • Aug 14Final Bids Reportedly Expected for HealiusAt least three suitors competing for the Healius Limited (ASX:HLS) diagnostic imaging business are preparing to lob their final offers this week, with questions arising over whether the company will achieve the $700 million price tag earlier expected for the business. DataRoom understands that Pacific Equity Partners, advised by Stanton Road Partners and Bank of America, TPG Capital, L.P., which has been working with consultant Bain and Company, and the Morgan Stanley-advised IFM have made it through to round two. Final bids were due on 12 August 2024, but this has been extended to this 15 August 2024. After the final bids have landed, an opportunity for due diligence will be offered in the UBS-advised competition. Expectations are that offers will be close to $700 million, but may fall slightly below that number as the business faces challenges linked to rising staff costs and the need for future investment as Healius makes capital spending on its pathology a priority. Healius is selling its Lumus Imaging unit to drive down its debt and fund its pathology arm, despite the imaging operation being the stronger performer.공시 • Aug 02Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024Healius Limited announced that Ravi Jeyaraj will step down as a Non-executive Director of Healius effective 2 August 2024. Mr. Jeyaraj has accepted a new role based full-time in Singapore and, in the best interests of shareholders, he has decided to step down from the Healius Board. Ravi has been non-executive Director since November 2023.공시 • Jul 15Macquarie Unit Reportedly in Healius RaceSuitors interested in buying the $700 million diagnostic imaging unit of Healius Limited (ASX:HLS) lodged their first round bids on July 12, 2024. Sources believe Macquarie Group's Macquarie Asset Management Inc. - normally an adviser - put in an offer for Lumus Imaging, either as a joint bidder or a suitor in its own right. MAM's interest would rival that of infrastructure investor IFM, which is bidding for Lumus with Morgan Stanley as its adviser. It's clear that the business has strong appeal for investors seeking defensive assets with secure earnings, akin to infrastructure. As earlier reported, other groups that have taken a look include TPG Capital, Bain Capital and Partners Group. Pacific Equity Partners was interested, although the level of conviction was unclear. Adamantem Capital and Quadrant Private Equity were also mentioned as being interested early on. Sonic Healthcare, Medibank Private and Ramsay Health Care are expected to be in the bidding line-up. Meanwhile, sources believe that once Lumus Imaging is sold, suitors like EQT may be eager to make a play for the remaining pathology operation. UBS is working on the sale.주주 수익률PHCR.FUS HealthcareUS 시장7D0%0.5%1.8%1Yn/a14.5%28.4%전체 주주 수익률 보기수익률 대 산업: PHCR.F의 US Healthcare 산업 대비 성과를 판단하기에 데이터가 부족합니다.수익률 대 시장: PHCR.F의 US 시장 대비 성과를 판단하기에 데이터가 부족합니다.주가 변동성Is PHCR.F's price volatile compared to industry and market?PHCR.F volatilityPHCR.F Average Weekly Movementn/aHealthcare Industry Average Movement7.3%Market Average Movement7.2%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.0%안정적인 주가: PHCR.F의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine PHCR.F의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트19946,994Paul Andersonwww.healius.com.au힐리우스는 호주의 소비자 및 의료진에게 전문 진단 서비스를 제공합니다. 이 회사는 세 가지 부문을 통해 운영됩니다: 병리학, 이미징 및 기타. 진단 이미징 서비스, 개인 의료 실험실, 병리학 서비스를 제공합니다.더 보기Healius Limited 기초 지표 요약Healius의 순이익과 매출은 시가총액과 어떻게 비교됩니까?PHCR.F 기초 통계시가총액US$368.57m순이익 (TTM)-US$20.82m매출 (TTM)US$1.16b0.3x주가매출비율(P/S)-17.7x주가수익비율(P/E)PHCR.F는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표PHCR.F 손익계산서 (TTM)매출AU$1.79b매출원가AU$1.24b총이익AU$547.20m기타 비용AU$579.20m순이익-AU$32.00m최근 보고된 실적Dec 31, 2024다음 실적 발표일Aug 21, 2025주당순이익(EPS)-0.044총이익률30.61%순이익률-1.79%부채/자본 비율45.0%PHCR.F의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/07/20 14:30종가2025/04/22 00:00수익2024/12/31연간 수익2024/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Healius Limited는 19명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Saul HadassinBarrenjoey Markets Pty LimitedBenjamin BrayshawBarrenjoey Markets Pty LimitedLyanne HarrisonBofA Global Research16명의 분석가 더 보기
공시 • May 26Private Equity Reportedly Lines Up for Healius's Agilex SaleThe sale of Healius Limited's (ASX:HLS) Agilex Biolabs (Agilex Biolabs Pty. Ltd.) business is attracting a healthy queue of private equity interest. At least two firms are understood to be among those examining the bioanalytical laboratories group being sold via UBS. Local firm Genesis Capital is among the names being mentioned in the context of the process, though it is not clear whether the firm is formally involved. Crescent Capital, which has been active in the healthcare space, is understood not to be among the suitors this time around. Healius is understood to be confident of achieving at least $150 million to $200 million for the business - a sharp markdown on the $301 million it paid in 2021, when the acquisition was struck at 20 times forecast earnings before interest, tax, depreciation and amortisation and pathology assets were commanding top dollar amid the pandemic. Agilex subsequently underperformed against those expectations. Despite the sobering context, the interest is genuine. Bidders are said to believe there is meaningful performance upside in the business. Some of the parties circling Agilex are also understood to have looked at Nucleus Network, the early-phase clinical trials business, suggesting an appetite for scale in the segment. For Healius, a clean exit from Agilex would go some way toward shoring up a balance sheet under pressure following a significant profit downgrade last month that sent shares tumbling more than 19 per cent. With Healius carrying a market value of just $254 million, a buyer acquiring the whole company would effectively be getting the core pathology business for next to nothing - a dynamic that is unlikely to be lost on those now poring over the Agilex information memorandum.
공시 • Feb 04Healius Limited to Report Fiscal Year 2026 Results on Aug 09, 2026Healius Limited announced that they will report fiscal year 2026 results on Aug 09, 2026
공시 • Jan 27Healius Limited to Report First Half, 2026 Results on Feb 18, 2026Healius Limited announced that they will report first half, 2026 results on Feb 18, 2026
공시 • Aug 21Healius Limited Provides Earnings Guidance for the Full Year 2026 and 2027Healius Limited provided earnings guidance for the full year 2026 and 2027. For the 2026, the company expects revenue growth to be consistent with growth in second half of 2025, while maintaining a broadly flat labour cost base. For the 2027, the company continues to expect to achieve high single digit EBIT margins by June 2027.
공시 • Aug 19Healius Limited, Annual General Meeting, Oct 30, 2025Healius Limited, Annual General Meeting, Oct 30, 2025.
공시 • May 09Healius Limited to Report Fiscal Year 2025 Results on Aug 21, 2025Healius Limited announced that they will report fiscal year 2025 results on Aug 21, 2025
공시 • May 26Private Equity Reportedly Lines Up for Healius's Agilex SaleThe sale of Healius Limited's (ASX:HLS) Agilex Biolabs (Agilex Biolabs Pty. Ltd.) business is attracting a healthy queue of private equity interest. At least two firms are understood to be among those examining the bioanalytical laboratories group being sold via UBS. Local firm Genesis Capital is among the names being mentioned in the context of the process, though it is not clear whether the firm is formally involved. Crescent Capital, which has been active in the healthcare space, is understood not to be among the suitors this time around. Healius is understood to be confident of achieving at least $150 million to $200 million for the business - a sharp markdown on the $301 million it paid in 2021, when the acquisition was struck at 20 times forecast earnings before interest, tax, depreciation and amortisation and pathology assets were commanding top dollar amid the pandemic. Agilex subsequently underperformed against those expectations. Despite the sobering context, the interest is genuine. Bidders are said to believe there is meaningful performance upside in the business. Some of the parties circling Agilex are also understood to have looked at Nucleus Network, the early-phase clinical trials business, suggesting an appetite for scale in the segment. For Healius, a clean exit from Agilex would go some way toward shoring up a balance sheet under pressure following a significant profit downgrade last month that sent shares tumbling more than 19 per cent. With Healius carrying a market value of just $254 million, a buyer acquiring the whole company would effectively be getting the core pathology business for next to nothing - a dynamic that is unlikely to be lost on those now poring over the Agilex information memorandum.
공시 • Feb 04Healius Limited to Report Fiscal Year 2026 Results on Aug 09, 2026Healius Limited announced that they will report fiscal year 2026 results on Aug 09, 2026
공시 • Jan 27Healius Limited to Report First Half, 2026 Results on Feb 18, 2026Healius Limited announced that they will report first half, 2026 results on Feb 18, 2026
공시 • Aug 21Healius Limited Provides Earnings Guidance for the Full Year 2026 and 2027Healius Limited provided earnings guidance for the full year 2026 and 2027. For the 2026, the company expects revenue growth to be consistent with growth in second half of 2025, while maintaining a broadly flat labour cost base. For the 2027, the company continues to expect to achieve high single digit EBIT margins by June 2027.
공시 • Aug 19Healius Limited, Annual General Meeting, Oct 30, 2025Healius Limited, Annual General Meeting, Oct 30, 2025.
공시 • May 09Healius Limited to Report Fiscal Year 2025 Results on Aug 21, 2025Healius Limited announced that they will report fiscal year 2025 results on Aug 21, 2025
공시 • May 05Healius Limited Announces Fully Franked Special Dividend, Payable on 23 May 2025The Board of Directors of Healius Limited announced that it has resolved to determine to pay a fully franked Special Dividend of approximately $300 million or 41.3 cents per ordinary share. The Special Dividend of 41.3 cents per share will be fully franked. That franking credit equates to 17.7 cents per share or approximately $128 million. Ex-Dividend date is 9 May 2025, Dividend Record Date is 12 May 2025 and Payment date is 23 May 2025.
공시 • May 01Affinity Equity Partners (Australia) Pty Limited completed the acquisition of Lumus Imaging from Healius Limited (ASX:HLS).Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million on a cash, debt and equipment-lease free basis on September 23, 2024. Lumus Imaging reported pre AASB 16 EBITDA of AUD 51.3 million and pre AASB 16 EBIT of AUD 34.4 million for period ending June 30, 2024. The sale is subject to customary conditions, including approval by the Foreign Investment Review Board. The transaction is expected to close in 1Q CY2025. The proceeds from the sale will be used to reduce debt, support strategic execution in Pathology and return cash to shareholders. UBS Securities Australia Ltd acted as financial advisor and Bradley Russell, Natalie Bryce and Nicole Pedler of Healius Limited acted as legal advisor for Bradley Russell. As of April 17, 2025 Healius Limited (Healius) today announces that the sale of Lumus Imaging to funds managed by Affinity Equity Partners is now unconditional and the scheduled completion date is 1 May 2025 along with this all conditions precedent including Foreign Investment Review Board approval, have been met. Affinity Equity Partners (Australia) Pty Limited completed the acquisition of Lumus Imaging from Healius Limited (ASX:HLS) on May 1, 2025.
공시 • Feb 20Healius Limited Announces Board and Executive ChangesThe Directors of Healius Limited have appointed Mr. Neil Vinson as a Non-Executive Director of Healius to take effect on 1 March 2025. The Board notes that as Mr. Vinson is a current employee of Tanarra Capital, a substantial shareholder, he will not be an Independent director. Mr. Vinson holds a Master of Management (Finance) and a Bachelor of Chemical and Biomolecular Engineering from the University of Melbourne. He joined Tanarra Capital in early 2018 as an Investment Manager, overseeing public market, private equity, and venture capital investments. In this role, he has gained significant board-level and investment experience across healthcare, financial services, retail, and industrial sectors. Previously, Mr. Vinson worked at J.P. Morgan in the Corporate Derivatives and Strategic Solutions team, within the private-side markets business. Audit Committee Chair: Ms Kathy Ostin has been appointed as Chair of the Audit Committee, effective from 1 March 2025. Ms Ostin has been a Non-executive Director of Healius since December 2024 and replaces Charlie Taylor, who has served as the Audit Committee Chair since March 2024. Mr. Taylor remains a Non-executive Director of Healius and Member of the Audit and People & Governance Committees. Resignation of Company Secretary: Mary Weaver has resigned as a Company Secretary with effect from 28 February 2025. Stephen Humphries continues as a Company Secretary and Gillian Nairn will be the person responsible for communications with ASX in relation to Listing Rule matters.
공시 • Jan 15Healius Limited to Report First Half, 2025 Results on Feb 20, 2025Healius Limited announced that they will report first half, 2025 results on Feb 20, 2025
공시 • Nov 29Healius Limited Announces Board Changes, Effective 1 December 2024The Directors of Healius Limited have appointed Ms Kathy Ostin as an independent Non-Executive Director of the company and accepted the resignation of Mr. Gordon Davis, both to take effect on 1 December 2024. Kathy is an experienced non-executive director and audit and risk committee chair. She brings invaluable experience as a former partner of KPMG and will add to the range of the Board's skills in the areas of finance and accounting, audit, risk, governance and strategy. Gordon also served as Chair of both the Risk and Audit Committees during his tenure.
공시 • Sep 24Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million on September 23, 2024. The transaction is expected to close in 1Q CY2025. UBS Securities Australia Ltd acted as financial advisor and Herbert Smith Freehills acted as legal advisor for Healius Limited. Lumus Imaging reported pre AASB 16 EBITDA of AUD 51.3 million and pre AASB 16 EBIT of AUD 34.4 million for period ending June 30, 2024.
공시 • Sep 19Healius Limited, Annual General Meeting, Nov 15, 2024Healius Limited, Annual General Meeting, Nov 15, 2024.
공시 • Aug 19TPG Capital, PEP Reportedly Still Competing for Healius Lumus ImagingThe Healius Limited (ASX:HLS) Lumus Imaging sale process is shaping up as a two party battle, with TPG Capital, L.P. and Pacific Equity Partners believed to be the last contenders in the contest. "Final" bids for the unit were received on 15 August 2024, but the understanding is that additional due diligence will conducted and then binding bids will be received. IFM, which was considered the frontrunner in the competition, is out, largely because a turnaround approach is required. Such situations typically have less appeal to infrastructure investors like IFM, looking for a steady earnings stream. They're more suited to a private equity firm or a strategic group. Affinity Equity Partners has also left the contest. TPG Capital's bid is being spearheaded by the Australian country head for the US-based private equity firm, Vincent Wong, who is based in Melbourne. PEP, as earlier reported by DataRoom, is working with Stanton Road Partners and Bank of America. Its interest at the start of the auction was considered lukewarm at best, so it will be interesting to see how it progresses through the final stages. No doubt it would snap up Healius at the right price, but it's understood that the Australian listed healthcare provider is seeking about $700 million net, or after transaction and tax costs, with the gross asking price well over that amount. While the potential upside for any buyer could be substantial, it may be tough going in the early stage, with some saying a business clean up is needed. Lumus Imaging, advised by UBS, is the nation's third-largest diagnostic imaging operation behind Sonic and Permira's I-MED. Its earnings before interest, tax, depreciation and amortisation over the next year are forecast to be $60 million - $70 million. Diagnostic imaging is attractive to private equity, with artificial intelligence expected to create upside. Healius is selling its Lumus Imaging unit to drive down its debt and fund its pathology arm, despite the imaging operation being the stronger performer.
공시 • Aug 14Final Bids Reportedly Expected for HealiusAt least three suitors competing for the Healius Limited (ASX:HLS) diagnostic imaging business are preparing to lob their final offers this week, with questions arising over whether the company will achieve the $700 million price tag earlier expected for the business. DataRoom understands that Pacific Equity Partners, advised by Stanton Road Partners and Bank of America, TPG Capital, L.P., which has been working with consultant Bain and Company, and the Morgan Stanley-advised IFM have made it through to round two. Final bids were due on 12 August 2024, but this has been extended to this 15 August 2024. After the final bids have landed, an opportunity for due diligence will be offered in the UBS-advised competition. Expectations are that offers will be close to $700 million, but may fall slightly below that number as the business faces challenges linked to rising staff costs and the need for future investment as Healius makes capital spending on its pathology a priority. Healius is selling its Lumus Imaging unit to drive down its debt and fund its pathology arm, despite the imaging operation being the stronger performer.
공시 • Aug 02Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024Healius Limited announced that Ravi Jeyaraj will step down as a Non-executive Director of Healius effective 2 August 2024. Mr. Jeyaraj has accepted a new role based full-time in Singapore and, in the best interests of shareholders, he has decided to step down from the Healius Board. Ravi has been non-executive Director since November 2023.
공시 • Jul 15Macquarie Unit Reportedly in Healius RaceSuitors interested in buying the $700 million diagnostic imaging unit of Healius Limited (ASX:HLS) lodged their first round bids on July 12, 2024. Sources believe Macquarie Group's Macquarie Asset Management Inc. - normally an adviser - put in an offer for Lumus Imaging, either as a joint bidder or a suitor in its own right. MAM's interest would rival that of infrastructure investor IFM, which is bidding for Lumus with Morgan Stanley as its adviser. It's clear that the business has strong appeal for investors seeking defensive assets with secure earnings, akin to infrastructure. As earlier reported, other groups that have taken a look include TPG Capital, Bain Capital and Partners Group. Pacific Equity Partners was interested, although the level of conviction was unclear. Adamantem Capital and Quadrant Private Equity were also mentioned as being interested early on. Sonic Healthcare, Medibank Private and Ramsay Health Care are expected to be in the bidding line-up. Meanwhile, sources believe that once Lumus Imaging is sold, suitors like EQT may be eager to make a play for the remaining pathology operation. UBS is working on the sale.
